Sponsored by Elanco
For the first time in more than a decade, a new Janus kinase (JAK) inhibitor has been approved for veterinary use in the United States. In this episode of Clinician’s Brief Partner Podcast, Dr. Beth invites dermatologist Dr. Andrew Rosenberg to share everything practitioners need to know when it comes to using JAK inhibitors in practice, from the benefits of having options within the drug class to the implications of the boxed warning for the new option.
INDICATIONS
Zenrelia is indicated for control of pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
IMPORTANT SAFETY INFORMATION
Read the entire package insert before using this drug, including the Boxed Warning. For Full prescribing information call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Discontinue Zenrelia for at least 28 days to 3 months prior to vaccination and withhold Zenrelia for at least 28 days after vaccination. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Monitor dogs for infections because Zenrelia may increase susceptibility to opportunistic infections. Neoplastic conditions (benign and malignant) were observed during clinical studies. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. The most common adverse reactions were vomiting, diarrhea and lethargy. Zenrelia has not been evaluated in breeding, pregnant, or lactating dogs and concurrent use with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents has not been tested. For full prescribing information see package insert.
Zenrelia, Elanco, and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-US-24-2291
Contact us:
Podcast@briefmedia.com
Where to find us:
Twitter:
Instagram:
The Team:
Beth Molleson, DVM - Host
Sarah Pate - Producer & Project Manager, Brief Studio
Randall Stupka - Podcast Production & Sound Editing
